Toxicity — Unintended Adverse Effects of Cancer Therapies

Toxicity describes the degree of harm or physiological impairment inflicted upon healthy organs and tissues by an antineoplastic agent or therapeutic intervention. Oncologists classify toxicities by their onset and duration: acute toxicities manifest during or immediately after administration, whereas late or chronic toxicities may develop months or years following treatment completion. Common examples include myelosuppression, cardiotoxicity, hepatotoxicity, and gastrointestinal disturbances.

To measure and communicate side effects consistently, international oncology organisations utilise standardised frameworks such as the Common Terminology Criteria for Adverse Events (CTCAE). This grading scale ranks toxicities from Grade 1 (mild, asymptomatic) to Grade 4 (life-threatening) and Grade 5 (treatment-related death), providing an objective basis for dose adjustments, treatment interruptions, and supportive medical care.

Recognising toxicity allows patients and care teams to intervene early before mild symptoms progress into dangerous complications. Unmanaged toxicity can require emergency hospitalisation, reduce physical function, and compromise cancer control if critical doses must be delayed or permanently stopped. Open communication regarding side effects enables clinicians to prescribe effective supportive therapies—such as antiemetics, growth factors, or steroids—allowing patients to complete their recommended treatment courses with improved comfort and safety.

Toxicity is monitored via routine laboratory investigations, including full blood counts, liver function tests, and renal profiles before each treatment cycle. Cardiotoxicity is assessed using echocardiograms or electrocardiograms (ECGs). Biomarkers like cardiac troponins, thyroid stimulating hormone (TSH), and inflammatory markers are also tracked to detect organ stress prior to symptom emergence.

Toxicity is a consideration across all cancer types treated with systemic therapy or radiation. High rates of haematological toxicity often occur in leukaemias and lymphomas treated with intensive chemotherapy. Solid tumours like lung, breast, and colorectal cancers frequently involve toxicities from cytotoxic regimens, whilst patients receiving immune checkpoint inhibitors for melanoma or renal cell carcinoma face distinct immune-related adverse events.

Severe toxicity often necessitates dose reductions, treatment delays, or switching to alternative pharmaceutical agents. For instance, severe immunotherapy-related toxicity typically requires suspending the drug and administering high-dose systemic corticosteroids to suppress inflammation. In contrast, predictable toxicities are often proactively managed with supportive medicines, such as granulocyte colony-stimulating factors (G-CSF) to prevent neutropenia or prophylactic antiemetics to prevent chemotherapy-induced nausea.